BioVie Inc.

Equities

BIVI

US09074F2074

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.4848 ^USD	-0.84%		-0.35%	-61.52%

Mar. 11	BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities	CI
Mar. 04	Top Midday Decliners	MT

BioVie Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023

November 08, 2023 at 04:31 pm EST

BioVie Inc. reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported net loss was USD 10.71 million compared to USD 10.42 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.38 a year ago.

Diluted loss per share from continuing operations was USD 0.29 compared to USD 0.38 a year ago.

Latest news about BioVie Inc.

BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities	Mar. 11	CI
Top Midday Decliners	Mar. 04	MT
BioVie Prices $21 Million Offering of Shares, Warrants; Stock Slumps	Mar. 04	MT
North American Morning Briefing : Stock Futures Hover At Start of Busy Week	Mar. 04	DJ
BioVie Prices $21 Million Public Offering of Common Stock, Warrants	Mar. 04	MT
Sector Update: Health Care Stocks Rising Late Afternoon	Mar. 01	MT
Top Midday Gainers	Mar. 01	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Mar. 01	MT
BioVie Shares Rise as Alzheimer's, Parkinson's Drug Trials Show Potential Improvements	Mar. 01	MT
BioVie Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
Oppenheimer Adjusts BioVie Price Target to $5 From $12, Maintains Outperform Rating	Nov. 30	MT
BioVie Says Modified Phase 3 Trial for Alzheimer's Disease Treatment Missed Statistical Significance Amid Protocol Errors	Nov. 29	MT
BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer?s Disease	Nov. 29	CI
BioVie Reports 'Positive' Phase 2b Trial Data of BIV201 in Refractory Ascites	Nov. 13	MT
BioVie Inc. Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease - The Liver Meeting® 2023	Nov. 13	CI
BioVie Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 08	CI
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD - The Liver Meeting®? 2023	23-10-26	CI
North American Morning Briefing : Stock Futures Hit by Israel-Hamas Conflict; Oil Jumps	23-10-09	DJ
North American Morning Briefing : Stock Futures, -2-	23-10-02	DJ
BioVie Shares Rise After Completion of Last Patient Treatment Visit in Trial for Mild to Moderate Alzheimer's Disease	23-09-26	MT
North American Morning Briefing : Stock Futures -2-	23-09-25	DJ
BioVie Inc. Presents Data for NE3107 At 2023 International Congress of Parkinson?s Disease and Movement Disorders	23-08-28	CI
BioVie Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-16	CI
Biovie Inc. Announces Phase 3 Trial of Ne3107 in Alzheimer's Disease	23-07-18	CI
BioVie Inc. to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease	23-07-10	CI

Chart BioVie Inc.

Duration

Period

More charts

Company Profile

BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Companyâs drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.4848

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOVIE INC.	-61.52%	26.62M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs